INVO Fertility Reports 23% Revenue Growth to $2.0 Million in Q1 2026

INVO Fertility, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of approximately $2.0 million, a 23% increase from $1.6 million in the same period last year. The growth was primarily driven by increased clinic revenue from the Georgia joint venture and the recent acquisition of Family Beginnings, a fertility clinic in Indiana. Despite the revenue increase, the company incurred a net loss of approximately $5.5 million, compared to a net loss of $17.4 million in the first quarter of 2025, reflecting a significant reduction in losses year-over-year.

The company's operating expenses rose to $3.6 million in the first quarter of 2026, up from $2.8 million in the prior year, largely due to increased selling, general, and administrative expenses, which accounted for $2.2 million. This increase was attributed to higher professional fees, personnel costs, and general administrative expenses. Notably, INVO Fertility also recorded a loss of approximately $3.8 million related to changes in the fair value of warrants, a new expense category not present in the previous year.

Strategically, INVO Fertility completed the acquisition of Family Beginnings on February 18, 2026, for a total purchase price of $760,000, which included cash and Series D Preferred Stock. This acquisition is expected to enhance the company's clinical footprint and support its growth in the fertility services market. The company currently operates four fertility clinics in the United States and continues to pursue additional acquisitions to expand its operations.

Operationally, INVO Fertility reported a significant increase in cash reserves, ending the quarter with approximately $4.9 million, compared to $0.8 million a year earlier. The company raised $7.1 million through warrant exercises during the quarter, which was partially used to repay debt obligations. However, the company also noted a negative working capital of approximately $0.6 million as of March 31, 2026, indicating ongoing liquidity challenges. Looking ahead, INVO Fertility plans to focus on organic growth of its clinic revenue and pursue further acquisitions to achieve profitability.

The company’s management expressed optimism about the future, citing the growing demand for assisted reproductive technology (ART) services and the potential for further expansion in the market. However, they acknowledged the need for additional funding to support operations and growth initiatives, raising concerns about the company's ability to continue as a going concern if sufficient capital is not secured.